161058-83-9 | Nu2058

Packsize	Purity	Availability	Price	Discounted Price
1mg	99%	in stock	$22.00	$15.00
5mg	99%	in stock	$33.00	$23.00
10mg	99%	in stock	$52.00	$36.00
25mg	99%	in stock	$66.00	$46.00
50mg	99%	in stock	$92.00	$64.00
100mg	99%	in stock	$126.00	$88.00

Description

• Catalog Number: AA87409
• Chemical Name: Nu2058
• CAS Number: 161058-83-9
• Molecular Formula: C12H17N5O
• Molecular Weight: 247.2963
• MDL Number: MFCD05664734
• SMILES: Nc1nc(OCC2CCCCC2)c2c(n1)[nH]cn2
• NSC Number: 707619

Computed Properties

• Complexity: 271
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 18
• Hydrogen Bond Acceptor Count: 5
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 3
• XLogP3: 2.1

Literature

• 6-Oxo and 6-thio purine analogs as antimycobacterial agents.

  Bioorganic & medicinal chemistry 20130401

• The kinase inhibitor O6-cyclohexylmethylguanine (NU2058) potentiates the cytotoxicity of cisplatin by mechanisms that are independent of its effect upon CDK2.

  Biochemical pharmacology 20090515

• Identifying tumor cell growth inhibitors by combinatorial chemistry and zebrafish assays.

  PloS one 20090101

• Regiospecific microwave-assisted synthesis and cytotoxic activity against human breast cancer cells of (RS)-6-substituted-7- or 9-(2,3-dihydro-5H-1,4-benzodioxepin-3-yl)-7H- or -9H-purines.

  European journal of medicinal chemistry 20080801

• EmbR2, a structural homologue of EmbR, inhibits the Mycobacterium tuberculosis kinase/substrate pair PknH/EmbR.

  The Biochemical journal 20080301

• Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer.

  Oncogene 20071206

• Novel structural features of CDK inhibition revealed by an ab initio computational method combined with dynamic simulations.

  Journal of medicinal chemistry 20060824

• Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination.

  Journal of the American Chemical Society 20060510

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• N2-substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2.

  Journal of medicinal chemistry 20040715

• The development of a CDK2-docking site peptide that inhibits p53 and sensitizes cells to death.

  Cell cycle (Georgetown, Tex.) 20040101

• Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor.

  Nature structural biology 20021001

• Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives.

  Journal of medicinal chemistry 20020801